InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,736.32
(
0.54%
)
US TECH 100
19,586.80
(
1.20%
)
Dow Jones
42,063.65
(
0.72%
)
Brent Oil
73.22
(
-1.07%
)
Bitcoin
69,614.03
(
-0.85%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

gdollasign

Send PM Follow Ignore
Followers 6
Posts 973
Boards Moderated 0
Alias Born 06/08/2010

gdollasign

Re: DewDiligence post# 120692

Friday, 05/27/2011 3:41:33 PM

Friday, May 27, 2011 3:41:33 PM

Post# of 253509
Complete common sense speaking but wouldnt that lend to plain old bad planning in trial design?...3 times?? The only true marker that gets a drug of this type approved i.e. AMRN is to show an actual CV benefit (read fewer incidence). If AMRN cant show it then it will end up the same way as the others mentioned. If it can then we are a mere percentage of future market cap. I dont know if either the ANCHOR or MARINE results highlighted such a benefit. Guess I will have to look.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up